Status:

UNKNOWN

Role of SIRT1 in Regulation of Epithelial-to-mesenchymal Transition in Breast Cancer Lymph Nodes Metastasis

Lead Sponsor:

Peking University People's Hospital

Conditions:

Breast Cancer

Lymph Node Metastases

Eligibility:

FEMALE

Brief Summary

Luminal A breast cancer is a kind of breast cancer with low rate lymph node metastasis and good survival. But in clinical practice, Luminal A breast cancer can present with early, unexpected lymph nod...

Detailed Description

The study has three parts. 1. In large specimens of human Luminal A breast cancer with T1 tumor and positive axillary lymph node, study the difference expression of SIRT1 and related p53, Bcl-2, auto...

Eligibility Criteria

Inclusion

  • Invasive breast cancer Luminal A subtype T1 and lymph node positive or T2/T3 with negative lymph node

Exclusion

  • Missing clinical pathology data

Key Trial Info

Start Date :

January 1 2019

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

December 30 2020

Estimated Enrollment :

160 Patients enrolled

Trial Details

Trial ID

NCT04137406

Start Date

January 1 2019

End Date

December 30 2020

Last Update

October 24 2019

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Peking university people's hospital

Beijing, Beijing Municipality, China, 100044

Role of SIRT1 in Regulation of Epithelial-to-mesenchymal Transition in Breast Cancer Lymph Nodes Metastasis | DecenTrialz